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Bicuspid aortic valve (BAV) is the most common type of congenital cardiac malformation. Patients with a BAV have a predisposition
for the development of thoracic aortic aneurysm (TAA). This pathological aortic dilation may result in aortic rupture, which is fatal
in most cases. The abnormal aortic morphology of TAAs results from a complex series of events that alter the cellular structure
and extracellular matrix (ECM) composition of the aortic wall. Because the major degeneration is located in the media of the
aorta, most studies aim to unravel impaired smooth muscle cell (SMC) function in BAV TAA. However, recent studies suggest that
endothelial cells play a key role in both the initiation and progression of TAAs by influencing the medial layer. Aortic endothelial cells
are activated in BAV mediated TAAs and have a substantial influence on ECM composition and SMC phenotype, by secreting several
key growth factors and matrix modulating enzymes. In recent years there have been significant advances in the genetic and
molecular understanding of endothelial cells in BAV associated TAAs. In this review, the involvement of the endothelial cells in BAV
TAA pathogenesis is discussed. Endothelial cell functioning in vessel homeostasis, flow response and signalling will be highlighted to
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Abstract  17 
Bicuspid aortic valve (BAV) is the most common type of congenital cardiac malformation. 18 
Patients with a BAV have a predisposition for the development of thoracic aortic aneurysm 19 
(TAA). This pathological aortic dilation may result in aortic rupture, which is fatal in most 20 
cases. The abnormal aortic morphology of TAAs results from a complex series of events that 21 
alter the cellular structure and extracellular matrix (ECM) composition of the aortic wall. 22 
Because the major degeneration is located in the media of the aorta, most studies aim to 23 
unravel impaired smooth muscle cell (SMC) function in BAV TAA. However, recent studies 24 
suggest that endothelial cells play a key role in both the initiation and progression of TAAs by 25 
influencing the medial layer. Aortic endothelial cells are activated in BAV mediated TAAs 26 
and have a substantial influence on ECM composition and SMC phenotype, by secreting 27 
several key growth factors and matrix modulating enzymes. In recent years there have been 28 
significant advances in the genetic and molecular understanding of endothelial cells in BAV 29 
associated TAAs. In this review, the involvement of the endothelial cells in BAV TAA 30 
pathogenesis is discussed. Endothelial cell functioning in vessel homeostasis, flow response 31 
and signalling will be highlighted to give an overview of the importance and the under 32 




Bicuspid aortic valve (BAV) is the most common congenital cardiovascular malformation 35 
with a prevalence of 0.5–1.5% in the general population and a male predominance of about 36 
3:1 (Roberts, 1970;Basso et al., 2004). In this anomaly, the aortic valve consists of 2 leaflets 37 
instead of the regular 3 leaflets. The BAV usually exhibits normal function at birth and during 38 
early life, however in adulthood BAV patients can develop several serious complications such 39 
as valvular stenosis and/or regurgitation, aortic dilation and thoracic aortic aneurysms (TAA). 40 
Although TAAs occur both in tricuspid aortic valves (TAV) and BAV, it has been estimated 41 
that 50%–70% of BAV patients develop aortic dilation and approximately 40% of BAV 42 
patients develop TAAs (Yuan et al., 2010;Saliba and Sia, 2015). Moreover, patients with a 43 
BAV have a 9-fold higher risk for aortic dissection compared to the general population 44 
(Lewin and Otto, 2005). To monitor dilation progression in BAV patients the aortic diameter 45 
is regularly measured using echocardiography. However, no treatment options are available to 46 
prevent dilation or impact on the remodelling aortic wall. Surgical intervention with the aim 47 
to prevent rupture is therefore currently the only therapy for TAAs.  48 
Thoracic aortic aneurysm 49 
While smooth muscle cells (SMCs) in the healthy media have a contractile phenotype, they 50 
are not terminally differentiated. This ensures the ability to regenerate the vessel wall after 51 
injury. This flexible change between cellular phenotypes is called “phenotypic switching”, 52 
with the contractile and synthetic SMCs on opposite sides of the spectrum. After phenotypic 53 
switching the synthetic SMCs can migrate towards a wounded area by secreting proteinases to 54 
break down the ECM. Synthetic SMCs also proliferate and produce ECM to repair the wall. 55 
When the vessel wall is repaired, synthetic SMCs will re-differentiate towards a contractile 56 
phenotype. TAA is characterized by phenotypic switching of contractile to synthetic SMCs 57 
and fragmentation of elastic lamellae (Figure 1). The BAV aorta is more prone to TAA 58 
development, possibly due to differences in vascular homeostasis. For example, it has been 59 
shown that non-dilated BAV aorta, like the dilated TAV aorta, has an increased collagen 60 
turnover (Wagsater et al., 2013). Moreover, orientation, fiber thickness and collagen 61 
crosslinking is altered in the dilated BAV aorta compared to the TAV aorta (Tsamis et al., 62 
2016). Additionally, decreased expression levels of lamin A/C, α-smooth muscle actin (α-63 
SMA), calponin and smoothelin were not only found in dilated, but also in non-dilated BAV 64 
aorta (Grewal et al., 2014). Abdominal aortic aneurysms (AAA) share some common features 65 
with TAA, but differ in that atherosclerosis plays a major role in AAA, whereas medial 66 
degeneration is characteristic of TAA (Guo et al., 2006). 67 
The mechanism initiating thoracic aortic dilation is thus far unknown, however, the 68 
two main hypotheses are that either an altered flow greatly impacts vessel wall homeostasis 69 
(flow hypothesis) or that an intrinsic cellular defect contributes to the formation of BAV as 70 
well as to the dilation of the aorta in these patients (genetic hypothesis) (Girdauskas et al., 71 
2011a). Several genes related to structural proteins have been found mutated in BAV patients, 72 
such as ACTA2, MYH11. Furthermore, in BAV patients multiple mutations have also been 73 
found in genes related to signalling proteins such as NOTCH1 and genes related to the TGFβ 74 
signalling pathway (Girdauskas et al., 2011b;Tan et al., 2012;Andelfinger et al., 2016). In 75 
addition to isolated cases, BAV has also been demonstrated to occur within families 76 
(Huntington et al., 1997;Calloway et al., 2011). Interestingly, 32% of the first-degree relatives 77 
of BAV patients with a TAV also develop aortic root dilation, suggesting that the genetic 78 
predisposition for BAV and TAA overlap or may be identical in these families (Biner et al., 79 
2009). However, a clear inheritance pattern remains to be found. TAAs are also observed in 80 
patients with other syndromes such as Marfan, Loeys–Dietz and Ehler–Danlos, but 81 
contrastingly, BAV seldom occurs in these syndromes (El-Hamamsy and Yacoub, 82 
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2009;Ruddy et al., 2013). For an overview of genetic variation associated with BAV and the 83 
effect on endothelial functioning see Table 1. 84 
Endothelial cells in vessel homeostasis 85 
Due to the obvious medial degeneration in the aortic wall, research in the past decades has 86 
focussed on characterizing the organization and SMC phenotype of the aortic media during 87 
dilation and aneurysm (Wolinsky, 1970;Halloran et al., 1995;Ruddy et al., 2013). Therefore, 88 
despite their main regulatory function, endothelial cells have so far taken the back seat in 89 
research towards understanding and treating aortic dilation. However, there is growing 90 
evidence that endothelial cells play an important role in the development and progression of 91 
aortic dilation.  92 
Endothelial cells line the lumen of the aorta which, together with some ECM and the 93 
internal elastic lamella, form the intima. As the layer between the blood (flow) and the main 94 
structural component of the aorta (the media) the function of endothelial cells is to 95 
communicate the signal between these two layers. Upon flow and stimuli such as 96 
inflammatory cytokines, signalling pathways like TGFβ, angiotensin and nitric oxide (NO) 97 
allow endothelial cells to directly target the contraction status of SMCs or indirectly target the 98 
SMC contractile phenotype to influence vessel wall functioning (Figure 2). Primary cilia on 99 
the luminal surface of the endothelial cells enable mechanosensing and signalling (Egorova et 100 
al., 2012). Endothelial cells lacking cilia change towards a mesenchymal phenotype, a process 101 
called endothelial to mesenchymal transformation (EndoMT) in which endothelial specific 102 
genes such as VE-cadherin and PECAM1 are down-regulated, whereas mesenchymal genes 103 
such as αSMA and fibronectin are up-regulated (Egorova et al., 2011). Intriguingly, a recent 104 
study demonstrated that Ift88
fl-fl
 mice crossed with Nfatc
Cre
, thereby lacking a primary cilium 105 
specifically in endothelial cells, display a highly penetrant BAV (Toomer et al., 2017)(Table 106 
1).  107 
The influence of flow on endothelial functioning and vessel homeostasis 108 
The flow pattern of blood from the heart into the aorta is altered by a BAV (Barker et al., 109 
2012). This difference between TAV and BAV hemodynamics in the aorta can be beautifully 110 
demonstrated using 4D MRI. Compared to a TAV, BAV generate a high velocity ‘jet’ 111 
propelling at an angle against the wall in the BAV aorta. This jet stream also causes an 112 
increase in peak shear stress on the endothelial cells (Barker et al., 2012). As mentioned 113 
above, aside from the genetic hypothesis, the altered flow is also hypothesized to cause the 114 
aortic dilation in BAV. 115 
It has been long known that adjusting flow induces remodelling of the vessel wall. 116 
Already, more than 30 years ago it was published that by decreasing blood flow in the carotid 117 
artery of rabbits by 70%, the lumen size of the vessel was decreased by 21% to compensate 118 
for the decreased blood flow (Langille and O'Donnell, 1986). Vascular remodelling is induced 119 
by increased shear stress on endothelial cells to restore original shear forces on the wall 120 
(Baeyens et al., 2016a). That flow greatly impacts endothelial functioning is also portrayed by 121 
the localization of fatty streaks and atherosclerosis at branch points and curves of arteries 122 
(Baeyens et al., 2016a). The turbulent flow at these locations causes dysfunctional 123 
endothelium: endothelial cells undergo apoptosis or exhibit increased proliferation. Moreover, 124 
permeability is increased, allowing LDL penetration into the intima as well as inflammatory 125 
cell adhesion and infiltration. Laminar flow induces the opposing quiescent endothelial 126 
phenotype characterized by a low turnover, alignment in the direction of the flow, decreased 127 
expression of inflammatory adhesion molecules like I-CAM and a low permeability caused by 128 
increased cell-cell adhesion molecules such as N-CAM and E-cadherin (Chistiakov et al., 129 
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2017). Experiments using co-culture of endothelial cells and SMCs revealed that flow on 130 
endothelial cells can also impact the phenotype of the underlying SMCs. Laminar shear stress 131 
on endothelial cells induces a contractile phenotype in synthetic SMCs, shown with both co-132 
culture experiments of endothelial cells under flow with SMCs, as by adding conditioned 133 
medium from flow exposed endothelial cells to SMCs (Tsai et al., 2009;Zhou et al., 2013). 134 
Upon laminar flow, endothelial cells signal towards SMCs using, for example, microRNA 135 
(miR)-126, prostacyclin, TGFβ3 and NO (Noris et al., 1995;Tsai et al., 2009;Walshe et al., 136 
2013;Zhou et al., 2013) MiR-126 in endothelial microparticles (EMPs) decreases SMC 137 
proliferation and neointima formation (Jansen et al., 2017). Interestingly, EMP secretion is 138 
elevated in BAV associated TAA (Alegret et al., 2016). It is believed that EMPs are formed 139 
when endothelial cells are trying to avoid undergoing apoptosis, possibly explaining the 140 
association of elevated levels of EMPs with vascular diseases such as diabetes, congestive 141 
heart failure and acute coronary syndrome (Rossig et al., 2000;Bernal-Mizrachi et al., 142 
2003;Tramontano et al., 2010).  143 
MiR-126 is only one means by which endothelial cells can impact on the vascular 144 
homeostasis. The main signalling pathways involved in BAV TAA and endothelial cells will 145 
be discussed in the next paragraphs.  146 
Angiotensin II signalling in TAA 147 
One of the major signalling pathways disturbed in aortic dilation is the Renin-Angiotensin-148 
Aldosterone-System (RAAS), which is important for maintaining blood pressure. By 149 
constriction/relaxation of blood vessels and altering water retention of the kidneys, the blood 150 
pressure is regulated. The juxtaglomerular cells in the kidney and baroreceptors in vessel wall 151 
can sense arterial blood pressure. Upon a drop in pressure, renin is released by the 152 
juxtaglomerular cells and renin then converts angiotensinogen into angiotensin I (ANGI), 153 
which in turn is converted by angiotensin converting enzyme (ACE) into angiotensin II 154 
(ANGII). Amongst others, ANGII can cause contraction of the SMCs to increase blood 155 
pressure. This contraction is caused by the binding of ANGII to the angiotensin II type 1 156 
receptor (AT1) on the SMCs, which in a cascade via Ca
+
/calmodulin, activates the myosin 157 
light chain (MLC) kinase and rapidly phosphorylates MLC, causing contraction of SMCs. In 158 
addition, ANGII stimulates the cortex of the adrenal gland to secrete aldosterone, which 159 
increases water resorption in the kidney. 160 
Aside from this direct vasoconstrictive effect, prolonged RAAS activation has diverse 161 
pathological effects. Aldosterone has been shown to cause endothelial dysregulation as well 162 




 mice demonstrated to cause progressive TAAs and AAAs (Daugherty et al., 164 
2000;Daugherty et al., 2010). The administration of ANGII in these mice decreased αSMA 165 
and calponin expression in the mouse aortas (Leibovitz et al., 2009;Chou et al., 2015). 166 
Moreover, ACE2 expression was increased in mouse aortas after ANGII infusion as well as in 167 
dilated aortas of BAV patients (Patel et al., 2014). ACE insertion/deletion polymorphisms 168 
were also identified as risk factor for the development of TAA in BAV patients (Foffa et al., 169 
2012). Furthermore, a correlation was found between chronic elevated levels of ANGII and 170 
endothelial cell dysfunction in patients with hyperaldosteronism, underlining the importance 171 
of the RAAS system and endothelial functioning (Matsumoto et al., 2015).  172 
A seminal study performed by Rateri and colleagues, displayed the importance of 173 
endothelial cell functioning in the ANGII aneurysm model (Rateri et al., 2011). Interestingly, 174 
mice with specific deletion of AT1 in SMCs or monocytes still developed aortic aneurysms 175 
following a chronic ANGII infusion, while endothelial specific knock-out of AT1, did not 176 
exhibit dilation of the thoracic aorta. This study indicates that the primary target cell for 177 
ANGII in this model is the endothelial cell, which in turn influences the SMCs, causing the 178 
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aortic structure to break down. How exactly this ANGII-endothelial cell signalling affects the 179 
SMC phenotype remains a crucial and intriguing question to be investigated. The same group 180 
one year later showed that AAA are not inhibited in the endothelial cell specific AT1 knock-181 
out, elegantly demonstrating that indeed there is a difference in pathogenesis between TAA 182 
and AAA (Rateri et al., 2012). This difference might be explained by a more prominent role 183 
for the adventitia than the intima in AAA development, or the developmentally different 184 
origin of SMCs in different parts of the aorta (Police et al., 2009;Tieu et al., 2009;Tanaka et 185 
al., 2015;Sawada et al., 2017).  186 
Aside from studies to understand the pathogenesis of TAA, ANGII treatment to model 187 
aortic aneurysm in mice is also used in the search of new treatment options. A recent study 188 
displayed that by treating ANGII infused mice with a combination therapy of Rosuvastatin 189 
and Bexarotene (retinoid X receptor-α ligand), aneurysm development was inhibited 190 
(Escudero et al., 2015). Moreover, they showed that this combination therapy affected 191 
endothelial cell proliferation, migration and signalling. In addition, upon ANGII treatment the 192 
VEGF secretion by endothelial cells in vitro was decreased (Escudero et al., 2015). Culture of 193 
SMCs from BAV patients exhibited an increase in AT1R expression, which was reduced to 194 
the levels of control SMCs after treatment with losartan (Nataatmadja et al., 2013). 195 
Interestingly, antagonizing TGFβ by blocking the AT1 receptor using Losartan in a Marfan 196 
disease model mouse (FBN1 mutation) demonstrated promising results for preventing and 197 
even reversing aortic dilation (Habashi et al., 2006). Furthermore, several clinical studies in 198 
Marfan patients reveal similar exciting results. However, a meta-analysis of clinical studies 199 
towards Losartan in Marfan patients did not show a reduction of aortic dilation in Losartan 200 
treated patients (Gao et al., 2016). Losartan treatment in BAV patients has not been 201 
investigated yet. A clinical study was initiated, but recently terminated due to low enrolment.* 202 
Therefore, the effect of Losartan on BAV TAA still needs to be determined. 203 
Notch1 signalling in TAA 204 
Notch signalling plays an important role in cardiovascular development (Niessen and Karsan, 205 
2008). In contrast to many signalling pathways, Notch signalling is cell-cell contact 206 
dependent. There are 4 Notch homologues of which Notch1 is the best known. Binding of 207 
Notch1 ligands Jagged1, Jagged2 and/or Delta expressed in one cell induces cleavage of the 208 
receptor and nuclear translocation of the intracellular domain in the other cell causing 209 
transcription of, amongst others, the HES/HEY gene family, key regulators in EndoMT 210 
(Noseda et al., 2004). Notch1 signalling induces EndoMT in endothelial cells and promotes a 211 
contractile phenotype in SMCs (Tang et al., 2010). Moreover, Notch1 signalling is required 212 
for angiogenesis (Krebs et al., 2000).  213 
Notch signalling was displayed to be crucial for normal development of the aortic 214 
valve and outflow tract amongst others, as determined in NOTCH1
-/-
 mice (High et al., 2009). 215 
Specifically in the neural crest cells, Notch signalling is important. It was found that 216 
disruption of endothelial Jagged1 signalling to Notch on neural crest cells, inhibits SMC 217 
differentiation (High et al., 2008). The Notch signalling pathway, as well as the TGFβ 218 
signalling pathway, is involved in EndoMT occurring in the outflow tract cushions, where 219 
endothelial cells change to populate the developing cardiac valves (Niessen et al., 2008). 220 
Thereby EndoMT is a crucial part of aortic valve development. Previous studies hypothesised 221 
that EndoMT may also play a role in the pathogenesis of BAV. Additionally, genes involved 222 
in this process such as NOTCH1, TGFBR2 and SMAD6, have been found to cause BAV in 223 
mouse models, as well as being linked to BAV in human studies (Garg et al., 224 
2005;Girdauskas et al., 2011b;Tan et al., 2012;Andelfinger et al., 2016;Gillis et al., 225 
2017;Koenig et al., 2017). Mice with NOTCH1 missense alleles have been characterized with 226 




demonstrated that specifically endothelial Notch1 signalling is required for normal outflow 228 
tract and valve development (Koenig et al., 2016). Moreover, a NOTCH1 mutation was found 229 
in a family with BAV, underscoring Notch1 as an important signalling pathway in BAV 230 
(Garg et al., 2005). These mutations have been associated with an increased risk of calcific 231 
aortic valve disease (CAVD), explained by the normally repressive function of Notch on 232 
calcification in valvular cells (Garg et al., 2005;Nigam and Srivastava, 2009;Kent et al., 233 
2013). Additionally, one study reported severely calcified valves in BAV patients with 234 
Cornelia de Lange syndrome, a disease caused by dysfunctional Notch signalling (Oudit et al., 235 
2006).  236 
Aside from the role of Notch signalling in valve formation, proper Notch signalling is 237 
also important for the homeostasis of the aorta, as illustrated by several studies. The non-238 
dilated aorta of BAV patients showed increased Notch signalling and EndoMT marker 239 
expression based on proteomic analysis (Maleki et al., 2016). Furthermore, a study using 240 
endothelial cells isolated from BAV aorta demonstrated decreased Notch1, Notch4 and DLL4 241 
mRNA levels compared to TAV non-aneurysmal tissue (Kostina et al., 2016). Moreover, 242 
upon TGFβ stimulation, there was a defective Notch dependent EndoMT response. 243 
Endothelial marker proteins such as VWF and PECAM, were unchanged between BAV and 244 
TAV endothelial cells. However, EndoMT markers HES1 and SLUG were significantly less 245 
upregulated in BAV endothelial cells compared to TAV endothelial cells. In addition, JAG1 246 
expression is normally upregulated upon Notch1 signalling and acts as a positive feedback-247 
loop. This upregulation of Jagged1 was decreased in BAV endothelial cells, explaining at 248 
least part of the dysfunctional Notch signalling in BAV patients with TAA (Kostina et al., 249 
2016).  250 
Interestingly, Notch1 plasma levels in combination with TNFα-converting enzyme 251 
were shown to correlate highly with the presence of AAA (Wang et al., 2015). Furthermore, 252 
studies demonstrated that NOTCH1haploinsufficiency or Notch1 inhibition can prevent or 253 
reduce the formation of AAA in ANGII infused mice (Hans et al., 2012;Cheng et al., 2014). 254 
However, the similarity in Notch signalling between AAA and TAA is debatable, as it has 255 
been displayed that in descending TAA tissue, in contrast to the ascending TAA, the SMCs 256 
exhibit a decreased Notch1 signalling, emphasizing the importance of the local environment 257 
in the aortic aneurysm formation (Zou et al., 2012).  258 
eNOS signalling in TAA 259 
Nitric oxide (NO) is produced when NO synthase (NOS) converts arginine into citrulline, 260 
releasing NO in the process. NOS was originally discovered in neurons (nNOS/NOS1), after 261 
which inducible NOS (iNOS/NOS2) and endothelial NOS (eNOS/NOS3) were found. eNOS 262 
phosphorylation increases NO production and is induced by factors such as shear stress, 263 
acetylcholine and histamine. NO has a very short half-life of a few seconds, making it a local 264 
and timely signal transducer. Endothelial secreted NO diffuses into the SMC where it relaxes 265 
the cell by increasing the calcium uptake into the sarcoplasmic reticulum: NO stimulates the 266 
sarco/endoplasmic reticulum ATPase (SERCA), and thereby decreases cytoplasmic Ca
+
 267 
levels. (Van Hove et al., 2009) Additionally, NO has also been revealed to regulate gene 268 
transcription by reacting with NO sensitive transcription factors (Bogdan, 2001). Finally NO 269 
has been shown to impact the SMC inflammatory status, however more research is required to 270 
fully understand the effect of NO on SMC phenotype (Shin et al., 1996). Uncoupled eNOS 271 
causes free oxygen radicals to be formed, which damages proteins and DNA.  272 
Multiple studies have identified an important role for dysregulated endothelial NO 273 
signalling in aneurysm development. For example, it has been demonstrated that the oxidative 274 
stress is increased in the media of the aortas of BAV patients compared to TAV aortas 275 




rapidly developed AAA and aortic rupture upon ANGII infusion, whereas wild-type (WT) 277 
mice did not display this phenotype (Gao et al., 2012). Re-coupling of eNOS by infusion of 278 
folic acid, inhibited AAA formation (Gao et al., 2012). A study investigating the effect of 279 
iNOS deletion in an elastase infusion mouse model of experimentally induced AAA did not 280 
demonstrate any substantial exacerbation of the aneurysm phenotype, indicating the 281 
importance of endothelial NO in aneurysm formation (Lee et al., 2001). Intriguingly, a 282 
follow-up study identified plasma and tissue levels of the eNOS co-factor tetrahydrobiopterin, 283 
necessary for coupling of eNOS, correlate with aneurysm development in ApoE
-/-
 mice and 284 
HPH-1 mice (Siu and Cai, 2014). In line with these studies, it was shown that endothelial 285 
specific expression of reactive oxygen species, by an endothelial specific overexpression of 286 
NOX2, can cause dissection in WT mice upon ANGII infusion (Fan et al., 2014). Moreover, 287 
eNOS knockout mice develop BAV, underlining the importance of endothelial dysfunction in 288 
the formation of BAV and the related TAA (Lee et al., 2000).  289 
In patients with a TAV and TAA, profiling of the aortic tissue revealed that eNOS 290 
phosphorylation was increased via a miR-21 dependent mechanism (Licholai et al., 2016). 291 
MiR-21 is specifically upregulated by shear stress and causes PTEN mRNA degradation, 292 
allowing an increase in eNOS phosphorylation (Weber et al., 2010). Furthermore, BAV TAA 293 
patient aortic samples displayed increased eNOS expression and activation compared to TAV 294 
TAA controls (Kotlarczyk et al., 2016). These studies indicate an increased eNOS activity in 295 
TAA formation in BAV patients. Contrastingly, decreased eNOS expression has been found 296 
in 72,7% aortic samples of BAV patients (N=22) (Kim et al., 2016). In addition, a negative 297 
correlation between eNOS expression levels and aortic dilation in BAV patients was reported 298 
(Aicher et al., 2007).  299 
In conclusion, multiple studies have investigated eNOS in the BAV aorta, with 300 
contrasting outcomes (Aicher et al., 2007;Mohamed et al., 2012;Kim et al., 2016;Kotlarczyk 301 
et al., 2016). These discrepancies may be caused by differences between patient populations, 302 
location of the aortic sample used, stage of aortic aneurysm formation and the use of different 303 
control samples for comparison. Nonetheless, all these studies indicate that normal levels of 304 
coupled eNOS are necessary to maintain a healthy aortic wall.  305 
TGFβ signalling in TAA 306 
TGFβ signalling is mediated by binding of the ligand TGFβ to the TGFβ type 2 receptor, 307 
which recruits and phosphorylates a TGFβ type 1 receptor. While there is only one type 2 308 
receptor, TGFβ can signal via two TGFβ type 1 receptors, Activin-like kinase (ALK)1 and 309 
ALK5. Upon ligand binding, ALK5 can phosphorylate SMAD2 or SMAD3 and ALK1 can 310 
phosphorylate SMAD1, SMAD5 or SMAD8. The phosphorylated SMADs translocate into the 311 
nucleus with SMAD4 to induce the canonical signalling pathway. TGFβ can also signal via 312 
non-canonical pathways by activating PI3K/AKT, MAPK or NF-kB. Via the canonical and 313 
non-canonical pathways, TGFβ influences cell cycle arrest, apoptosis, inflammation, 314 
proliferation and more.  315 
In endothelial cells, TGFβ signalling can either inhibit or stimulate the cell growth and 316 
function depending on the context (Goumans and Ten Dijke, 2017). TGFβ signalling via 317 
ALK1 induces proliferation and migration, whereas ALK5 signalling promotes plasminogen 318 
activator inhibitor 1 (PAI1) expression, decreasing the breakdown of the ECM necessary for 319 
maturation of the vessel wall (Goumans et al., 2002;Watabe et al., 2003). The two opposing 320 
effects of TGFβ signalling enable the initial growth of vessels followed by stabilization of the 321 
ECM and attraction of SMCs. Moreover, endothelial TGFβ signalling in concert with platelet 322 
derived growth factor-BB is crucial for attracting and differentiating pre-SMCs during 323 
vasculogenesis (Hirschi et al., 1998). Because of these crucial functions of TGFβ during 324 




or SMC or endothelial cell specific deletion is embryonically lethal (Goumans and Ten Dijke, 326 
2017). In SMCs TGFβ induces a contractile phenotype, and dysregulation of TGFβ therefore 327 
can have a major impact on SMC phenotype (Guo and Chen, 2012). The importance of 328 
endothelial TGFβ signalling on SMC differentiation is illustrated by co-culture of endothelial 329 
cells and SMCs. Cultured alone, the SMCs have a synthetic phenotype, but when co-cultured 330 
with endothelial cells, they differentiate into contractile SMCs via the PI3K/AKT signalling 331 
pathway (Brown et al., 2005).  332 
The TGFβ Type III receptor endoglin (ENG) is highly expressed by endothelial cells 333 
and plays a role in the ALK1 and ALK5 signalling balance (Goumans et al., 2003). In fact, 334 
without endoglin, endothelial cells stop proliferating as a result of decreased ALK1 signalling 335 
(Lebrin et al., 2004). In addition, knock-out of ENG in mice causes embryonic lethality due to 336 
impaired angiogenesis, whereas vasculogenesis remains intact (Li et al., 1999;Arthur et al., 337 
2000). This exemplifies the pivotal role for TGFβ signalling in endothelial cells for proper 338 
angiogenesis. As mentioned above, TGFβ signalling, like Notch signalling, is important for 339 
the process of EndoMT necessary for the developing cardiac valves. Chimera research using 340 
ENG
-/-
 mice embryonic stem cells, added to WT mice morulae highlighted the indispensable 341 
role of endoglin for EndoMT in the developing cardiac valves (Nomura-Kitabayashi et al., 342 
2009). These chimeric mice showed contribution of the ENG
-/-
 cells to the endothelium. 343 
However, no ENG
-/-
 cells participated in populating the atrio-ventricular (AV) mesenchyme of 344 
the developing AV cushions. Intriguingly, a single-nucleotide polymorphism in ENG was 345 
found in BAV patients, indicating that in BAV patients endothelial TGFβ signalling might be 346 
altered, potentially promoting a phenotypic switch in the underlying SMCs (Wooten et al., 347 
2010). 348 
Many studies using in vitro, ex vivo and histological methods, also indicate a role for 349 
TGFβ signalling in TAA formation in BAV. Unstimulated, cultured BAV and TAV SMCs 350 
did not demonstrate any difference in gene expression in basal conditions, however after 351 
TGFβ stimulation, 217 genes were found differentially expressed between BAV and TAV 352 
SMCs demonstrating a difference in TGFβ signalling (Paloschi et al., 2015). Moreover, 353 
induced pluripotent stem cells (iPSCs) derived from BAV patients with a dilated aorta 354 
exhibited decreased TGFβ signalling compared with iPSCs from TAV controls without aortic 355 
dilation (Jiao et al., 2016). Conversely, a hypothesis-free analysis of the secretome of BAV 356 
TAA indicated a highly activated TGFβ signalling pathway in the aortic wall of BAV patients 357 
when compared to the secretome of TAV aneurysmal aortic tissue (Rocchiccioli et al., 2017). 358 
This study showed, using mass spectrometry on all proteins in conditioned medium of the 359 
aortic samples, a 10-fold increase of latent TGFβ binding protein 4 (LTBP4) in the BAV 360 
samples (Rocchiccioli et al., 2017). Histological analysis identified that, compared to normal 361 
aortic tissue, BAV dilated aortic tissue had an increase in SMAD3 and TGFβ in the tunica 362 
media (Nataatmadja et al., 2013). However, when compared to dilated TAV aorta, the 363 
expression of SMAD 2/3 was higher in the TAV dilated aorta than the BAV dilated aorta 364 
(Rocchiccioli et al., 2017). Furthermore, it has been shown that the circulating TGFβ levels in 365 
BAV patient are elevated, which is in agreement with studies showing increased TGFβ 366 
signalling (Hillebrand et al., 2014;Rueda-Martinez et al., 2017).  367 
Multiple studies have demonstrated that antagonizing TGFβ signalling in aneurysm 368 
mouse models prevents and even reverses aneurysm formation (Habashi et al., 2006;Ramnath 369 
et al., 2015;Chen et al., 2016). The positive effects of TGFβ antagonism on aneurysm 370 
formation were shown in using a neutralizing TGFβ-antibody or by blocking the AT1 371 
receptor using Losartan, which also decreases TGFβ signalling. In different mice models, 372 
Fibrillin-1 deficient, Fibulin-4 deficient and ANGII treated mice, the TGFβ inhibition 373 
prevented and reversed aortic aneurysm, making it a promising target for therapy (Habashi et 374 




Losartan treatment decreased intracellular TGFβ protein levels and nuclear SMAD3 376 
localization (Nataatmadja et al., 2013). BAV derived SMCs displayed a decrease in endoglin 377 
expression upon Losartan treatment (Lazar-Karsten et al., 2016). Furthermore, serum TGFβ 378 
levels decreased when mice were treated with Losartan. The same was also seen in Marfan 379 
patients on Losartan, validating the study results obtained in mice (Habashi et al., 2006;Matt 380 
et al., 2009). However, as mentioned above, so far Losartan treatment does not seem to 381 
decrease or prevent aneurysm formation in a clinical setting. Given the recent success of 382 
specific TGFβ blockers in other vascular disorders such as pulmonary arterial hypertension 383 
(PAH) and restenosis, targeting the TGFβ pathway more directly could be a strategy for 384 
developing new treatment modalities for TAA (Yao et al., 2009;Yung et al., 2016).  385 
Endothelial dysfunction in other diseases: implications for BAV-TAA? 386 
Many cardiovascular disorders have highlighted the importance of normal endothelial 387 
functioning for maintaining homeostasis across the vessel wall, such as atherosclerosis, brain 388 
aneurysms, PAH and hereditary haemorrhagic telangiectasia (HHT). PAH and HHT are 2 389 
major genetic diseases in which the role of the endothelial cells is well recognized. Two 390 
recent advances in these research fields worth mentioning for future perspectives in BAV 391 
TAA research, will be discussed in the next paragraphs.  392 
PAH is an incurable fatal disease caused by remodelling of the pulmonary arteries. 393 
Proliferation of the pulmonary artery smooth muscle cells (PASMCs) causes narrowing and 394 
occlusion of the lumen, leading to an increased pressure in the lungs and increased load of the 395 
right ventricle (Morrell et al., 2009). While originally defined as a SMC disorder, over the 396 
past years dysfunction of the endothelial cells has become of interest in the pathogenesis of 397 
PAH (Morrell et al., 2009;Sakao et al., 2009;Xu and Erzurum, 2011). The application of 398 
conditioned medium from normal endothelial cells to PASMCs resulted in an increase in 399 
PASMC proliferation rate (Eddahibi et al., 2006). This effect is exaggerated when adding 400 
conditioned medium of endothelial cells from PAH patients. Complementary, PASMCs from 401 
PAH patients showed an increased proliferation to both endothelial cell conditioned media, 402 
compared with control PASMCs. Two of the major players identified within the conditioned 403 
medium are miR-143 and miR-145. These miRs have been demonstrated to highly impact the 404 
SMC phenotypic switch, inducing a contractile phenotype (Boettger et al., 2009). Expression 405 
of these two miRs is regulated by TGFβ and they have been shown to be secreted in 406 
exosomes (Climent et al., 2015;Deng et al., 2015). Intriguingly, in PAH mouse models as well 407 
as patient lung tissue and cultured SMCs, miR-143-3p expression is increased. Furthermore, 408 
miR-143
-/- 
mice developed pulmonary hypertension, a phenotype that was rescued by 409 
restoring miR-143 levels (Deng et al., 2015). 410 
Interestingly, signalling from endothelial cells to SMCs concerning miR-143 and miR-411 
145 has also been investigated in atherosclerosis research (Hergenreider et al., 2012). 412 
Transduction of HUVECs with the shear-responsive transcription factor KLF2, or exposure of 413 
HUVECs to flow caused an increase in miR-143 and miR-145, indicating a flow 414 
responsiveness of the miR-143 and miR-145 expression (Hergenreider et al., 2012). 415 
Additionally, endothelial cells secreted miR-143 and miR-145 in microvesicles and targeted 416 
gene expression in SMCs. Moreover, when treating ApoE
-/-
 mice with endothelial secreted 417 
vesicles containing, amongst others, miR-143 and miR-145, the mice developed less 418 
atherosclerosis (Hergenreider et al., 2012). SMCs of miR143 and miR-145 knockout mice 419 
displayed increased migration and proliferation. In addition, analyses of the mouse aortas 420 
showed EMC degradation in the miR-143 and miR-145 deficient mice. These results support 421 
the findings of a role for miR-143 and miR-145 in inducing a contractile SMC phenotype 422 
(Elia et al., 2009). Furthermore, in TAA miR-143 and miR-145 were found to be decreased 423 




phenotype, the expression regulation by flow and their secretion by endothelial cells as well 425 
as the decrease in TAA, makes them relevant and interesting for BAV TAA research. The 426 
first study towards BAV and miR-143 and miR-145 was recently published, describing a local 427 
decrease of miR-143 and miR-145 in the inner curve of the BAV aorta compared to the outer 428 
curve. Moreover, they also found altered miR expression affecting mechanotransduction 429 
(Albinsson et al., 2017). 430 
Intriguingly, mechanotransduction has also been of interest in HHT research. HHT is a 431 
vascular disease characterized by frequent severe bleedings due to fragile and tortuous blood 432 
vessels. Disturbed TGF-beta signalling plays a major role in the development of these 433 
malformed blood vessels. 80% of HHT patients have a mutation in ENG (HHT1) or ALK1 434 
(HHT2) (McDonald et al., 2015). The endothelial cell-SMC communication is disrupted in 435 
HHT, and recruiting and differentiation of SMCs falters causing improperly formed vessels. 436 
Disturbed mechanotransduction in endothelial cells has been shown to impact BMP/Smad1/5 437 
signalling as well as vessel stabilization in HHT (Baeyens et al., 2016b). By subjecting 438 
endothelial cells to shear stress, SMAD1 was activated. Moreover, decreasing either ALK1 or 439 
endoglin both inhibited the SMAD1 activation in response to flow. Interestingly, when co-440 
cultured with pericytes, both ALK1 and endoglin were found to be crucial for endothelial 441 
shear stress induced migration and proliferation of these pericytes (Baeyens et al., 2016b). It 442 
would be highly interesting to investigate if BAV endothelial cells also have an intrinsic 443 
mechanotransduction defect causing the aorta to be prone to TAA development. The study by 444 
Albinsson and colleagues showing the altered miR related to mechanotransduction in BAV 445 
aorta samples is an important first step to lead the BAV TAA research field towards relevant 446 
studies on mechanotransduction defects possibly explaining (part of the) BAV TAA 447 
pathogenesis.  448 
Conclusions and future perspectives 449 
BAV is a common congenital cardiac malformation and the majority of BAV patients develop 450 
TAA over time. Although the last decade has witnessed the discovery of several key findings 451 
in the field of BAV-associated TAAs, the cellular and molecular mechanisms in BAV-452 
associated TAAs that drive the degeneration of media of the vessel wall are still largely 453 
unknown. Many studies have focussed on changes in the signalling pathways in SMCs, 454 
however the importance of endothelial cells and their contribution to the initiation and 455 
progression of BAV-associated TAAs has not been appreciated in detail.  456 
Under normal physiological conditions, endothelial cells and SMCs communicate with 457 
each other for optimal function of the vessel wall in order to maintain homeostasis in the 458 
circulatory system. Dysregulation of this communication can lead to medial degeneration and 459 
aortic aneurysm, clearly demonstrated in animal models using ANGII infusion or eNOS 460 
uncoupling. Interestingly, blocking TGFβ signalling is a possible treatment option to prevent 461 
TAA formation, as evidenced by multiple animal studies mentioned before. Patient samples 462 
also indicate a pivotal role for these pathways as revealed by the dysregulation of eNOS, 463 
Notch1 and TGFβ signalling proteins in the BAV aortic tissue. The involvement of these 464 
pathways is validated by the mutations that have been shown to cause BAV and/or TAA in 465 
mouse models and the finding of mutations in these genes in patients with BAV and TAA. In 466 
addition to these observations made in vivo, in vitro studies using patient derived endothelial 467 
cells indicate an EndoMT defect in cultured cells from BAV patients. In conclusion, all 468 
studies to date indicate great potential of an underexplored research field concerning the 469 
endothelial-smooth muscle cell communication in the BAV TAA formation. 470 
While hardly studied in BAV, the importance of endothelial functioning for vessel 471 




atherosclerosis. In line with the latest research in these fields, it would be very interesting to 473 
investigate if the mechanotransduction and/or microvesicle secretion is altered in endothelial 474 
cells of BAV TAA patients. Unfortunately, research towards endothelial cell contribution in 475 
BAV TAA pathogenesis has been hampered by the difficulty of obtaining non-end stage study 476 
material. The discovery of circulating endothelial progenitor cells (EPCs) and endothelial 477 
colony forming cells (ECFCs) will, however, provide a new study model, facilitating patient 478 
specific analysis of the endothelial contribution to the disease (Asahara et al., 1997;Ingram et 479 
al., 2004). Thus far, one study was published using these circulatory cells from BAV patients. 480 
An impaired EPC migration and colony formation potential was shown when the cells were 481 
isolated from BAV patients with a dysfunctional valve compared to BAV patients with a 482 
normal functioning valve (Vaturi et al., 2011). Currently, the cause and effect of impaired 483 
EPCs is unknown, and more research is required to understand the full potential of circulating 484 
endothelial progenitor cells in BAV TAA pathogenesis and their use as a biomarker for 485 
patient stratification.  486 
Although few studies on the role of endothelium in BAV disease and its associated 487 
TAAs have been performed in the last decade, some seminal papers have been published. In 488 
this review, we have created an overview of the recent studies implicating endothelial cells as 489 
a pivotal player of vascular homeostasis, and their underappreciated role in TAA pathogenesis 490 
in patients with a BAV. Figure 3 schematically depicts the different factors and processes 491 
involved in BAV TAA development as discussed throughout this review. Up to date, we are 492 
still unable to stratify and cure these patients. Therefore, further research is required to 493 
understand the role of endothelial cells and comprehend the interplay between endothelial 494 
cells and SMCs in BAV-associated TAA. In conclusion, appreciation of the role of 495 
endothelium is crucial for a better understanding of BAV TAA pathogenesis, which is 496 
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Figure 1. Structure of normal and diseased aortic wall. Images of aortic tissue showing 506 
elastic lamellae (stained with RF) or smooth muscle cells (SM22 staining) On the left is 507 
normal aortic tissue, the right image shows aortic tissue with fragmentation of the lamellae or 508 
loss of contractile SMCs.  509 
Figure 2. Schematic overview of signalling pathways between endothelial cells and SMCs. A 510 
simplified overview on the communication between endothelial cells and SMCs is depicted. 511 
Extensive crosstalk between pathways such as Notch1, ANGII, TGFβ and NO can influence 512 
proliferation and differentiation of SMCs and affect the phenotypic switch of SMCs.  513 
Figure 3. Schematic overview of events in development of aortic dilation. Schematic overview 514 
of an aorta over time. Initiation by flow and/or genetics causes endothelial cell dysfunction, 515 




Table 1 Consequences of genetics associated with BAV on cardiac malformations and endothelial cell functioning 517 
Pathway Mutation Effect 
Other cardiovascular 
malformations 
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